Evidence map›Paper›PMID 40844188›Full record

ArticleEpigenomics2025

Altered mitochondrial DNA methylation in blood in individuals with mild cognitive impairment.

Wuzi Tu, Ying Jin, Xiaohong Zhang, Xiaofei Ye, Li Hua, Nannan Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wuzi TuSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ying JinDapuqiao Community Health Service Center, Shanghai, China.
Xiaohong ZhangSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaofei YeSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li HuaSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nannan FengSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-0212-6171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies reported that altered mitochondrial methylation in Alzheimer's disease (AD), however, whether epigenetic modifications in mitochondrial genomes contribute to preclinical AD remains unclear. This study aimed to investigate mitochondrial methylation changes in individuals with cognitive decline. RESEARCH DESIGN AND

methodsWe examined whole mitochondrial genome methylation in 50 individuals with mild cognitive impairment (MCI) and 50 individuals without MCI, using bisulfite amplicon sequencing, assessing methylation at 366 Cytosine-guanine oligodeoxynucleotide (CpG) sites.

resultsWe found the overall methylation level of mitochondrial DNA (mtDNA) in each subject was relatively low, ranging from 0% to 15%. Global methylation was significantly higher in individuals with cognitive decline compared to controls (3.86% vs. 3.46%,

conclusionsOur study provides an mtDNA methylation map and suggests a role for these sites in preclinical AD pathogenesis.

Indexed as

Cognitive DysfunctionDNA MethylationDNA, MitochondrialAgedAged, 80 and overCase-Control StudiesCpG IslandsEpigenesis, GeneticFemaleHumansMaleMiddle AgedDNA, Mitochondrialbisulfite amplicon sequencingepigenetic biomarkersmild cognitive impairmentmitochondrial methylationWhole-genome

Identifiers

PMID40844188
PMCPMC12490357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.